GeneDx is trading at $68.36, up 5.23%, as of 10:34 a.m. ET on October 14, with no clear newly reported company-specific catalyst identified.

  • GeneDx’s GUARDIAN newborn-screening data and Easy Order launch were announced earlier in October; available reporting does not establish either as the direct cause of today’s rise.
  • The gain runs counter to the supplied market and biotech-sector declines, which do not explain the move.